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Abstract
Rationale—Research using a drug discriminated goal-tracking (DGT) task showed that the N-
methyl-D-aspartate (NMDA) channel blocker MK-801 (dizocilpine) reduced the nicotine-evoked
conditioned response (CR).
Objectives—Given the unknown mechanism of the effect, Experiment 1 replicated the MK-801
results and included tests with NMDA receptor ligands. Experiments 2a and 2b tested whether
MK-801 pretreatment blocked DGT via a state-dependency effect.
Methods—In Experiment 1, adult male Sprague–Dawley rats received intermittent access to
liquid sucrose following nicotine (0.4 mg base/kg); no sucrose was delivered on intermixed saline
sessions. Conditioning was indicated by increased anticipatory dipper entries (goal-tracking) on
nicotine compared to saline sessions. Antagonism and/or substitution tests were conducted with
MK-801, phencyclidine, CGP 39551, d-CPPene (SDZ EAA 494), Ro 25,6981, L-701,324, ACPC,
and NMDA. In Experiment 2a, rats received nicotine and sucrose on every session—no
intermixed saline sessions without sucrose. Tests combined MK-801 or the non-competitive
nicotinic acetylcholine receptor antagonist, mecamylamine with either nicotine or saline.
Experiment 2b had sucrose delivered on saline sessions and no sucrose on intermixed nicotine
sessions followed by MK-801 antagonism tests of the saline CS.
Results—MK-801 and phencyclidine dose-dependently attenuated the CR in Experiment 1.
Ro-25,6981 enhanced the CR, but did not substitute for nicotine. Other ligands showed
inconsistent effects. In Experiment 2a, MK-801 pretreatment reduced goal-tracking when given
before nicotine and saline test sessions; mecamylamine pretreatment had no effect. In Experiment
2b, MK-801 dose-dependently attenuated the saline-evoked CR.
Conclusions—Combined, the results suggest that MK-801 blocks discriminated goal-tracking
by virtue of state-changing properties.
Correspondence related to this article should be addressed to Jennifer E. Murray, Department of Experimental Psychology, Downing
Street, Cambridge, UK, CB2 3EB, or jem98@cam.ac.uk.
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Introduction
Drug states and their interoceptive effects likely play an important role in addiction. As
such, several animal models have been developed to study the interoceptive stimulus effects
of drugs including nicotine. The most widely used model is the two-lever operant drug
discrimination task with rats (see Rosecrans and Villanueva 1991; Smith and Stolerman
2009; Solinas et al. 2006) in which completion of a response requirement on one lever is
typically reinforced in the drug state, whereas responding on the other lever is not
reinforced. During intermixed vehicle sessions the reverse contingency applies. In rats,
stimulus control by the internal state is evidenced by a majority of responding on the drug-
appropriate lever (e.g., Chance et al. 1977; Desai et al. 2003; Stolerman et al. 1997; Wooters
et al. 2009).
More recently, a discriminated goal-tracking (DGT) task with rats has been used to study the
conditional stimulus (CS) effects of nicotine. In these studies, rats receive intermixed
nicotine and saline sessions (e.g., Besheer et al. 2004; Bevins and Palmatier 2004). On
nicotine sessions, access to sucrose is intermittently available in the chamber (see Murray et
al. 2009b for water reinforcement). On saline sessions, no sucrose is available. The
discrimination quickly develops as shown by increased anticipatory dipper entries (goal-
tracking; e.g., Farwell and Ayres 1997) on nicotine compared to saline sessions. This
conditioned response (CR) has been shown to be sensitive to manipulations such as nicotine
training dose (Murray and Bevins 2007a, b), number and concentration (w/v) of sucrose
delivered (Murray et al. 2009a; Wilkinson et al. 2006), and extinction training (Besheer et
al. 2004; Murray and Bevins 2007b).
Of primary interest in the present report was the earlier finding that MK-801, a non-
competitive channel blocker with high affinity for the N-methyl-D-aspartate (NMDA)
glutamate receptor (Halliwell et al. 1989; Wong et al. 1986), dose-dependently reduced
nicotine CS-evoked conditioned responding without affecting chamber activity (Murray and
Bevins 2007a). The finding in the DGT task was particularly interesting given that
pretreatment with MK-801 has not been found to block nicotine’s control of responding in
the two-lever operant drug discrimination task (Kim and Brioni 1995; Zakharova et al. 2005;
see Zaniewska et al. (2008) for tests with agmatine). One possible explanation for this
distinction is that the neurobiological mechanism underlying the CS effects of nicotine
(DGT) differ somewhat from those mediating its discriminative stimulus effects in the two-
lever task (cf. Murray et al. 2009b). If this hypothesis is correct, then more selective NMDA
receptor antagonists should also block conditioned responding evoked by nicotine in the
DGT task and provide additional information about the mechanism of the effect. As the
NMDA receptor complex involves multiple subtypes and binding sites, we tested a variety
of ligands with varying specificity to isolate the mechanism of this reduction in conditioned
responding. Accordingly, in Experiment 1 we tested a slightly lower affinity NMDA
channel blocker, phencyclidine (PCP; Wong et al. 1986), followed by competitive
antagonists that bind to the NMDA but not the glycine/D-serine binding site on the NMDA
receptor, CGP 39551 and d-CPPene (Fagg et al. 1990; Lowe et al. 1994), and a competitive
antagonist specific to the presynaptic NR2B binding subtype, Ro 25-6981 (Fischer et al.
1997). We also tested L-701,324, an antagonist with specificity for the glycine/D-serine
binding site of the NMDA receptor (Bristow et al. 1995), and 1-
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aminocyclopropanecarboxylic acid hydrochloride (ACPC), a glycine/D-serine agonist with
NMDA site antagonist actions (Sheinin et al. 2002), for antagonism and/or substitution for
the CS effects of nicotine.
Another possibility for the difference seen between the DGT and two-lever tasks is that
MK-801 has a state-dependency effect preventing recall of learning under some specific
conditions (see Tzschentke and Schmidt 2000). Notably, nicotine does not appear to have
this type of state-dependency. For example, rats previously trained to goal-track after
pretreatment with nicotine (no intermixed saline sessions) did not display an overall
reduction in responding when tested for the first time in the saline state. Similarly, rats
trained to goal-track after pretreatment with saline (no intermixed nicotine sessions) did not
show a significant reduction in responding when tested in the nicotine state. This outcome
was taken to suggest that the nicotine-evoked CR in the DGT task was not due to state-
dependent learning or recall (Bevins et al. 2007). If it had been, switching states would have
profoundly disrupted responding. Experiment 2a expanded this observation to determine
whether MK-801 would decrease a goal-tracking CR that was not under stimulus control of
the nicotine state. Rats were first trained to goal-track following pretreatment with nicotine
(no intermixed saline sessions) and then tested in a variety of ‘different’ states: saline,
mecamylamine+ nicotine, mecamylamine+saline, MK-801+nicotine, MK-801+saline. The
state-dependency account of a reduced CR predicts that MK-801 will reduce goal-tracking
regardless of whether tested in combination with saline or nicotine. In contrast, saline in
place of nicotine is not expected to reduce goal-tracking (cf. Bevins et al. 2007). Given that
in this training regimen saline sessions are not intermixed, nicotine is not controlling the CR
(chamber cues appear to be). As such, blocking nicotinic acetylcholine receptors with
mecamylamine is not expected to reduce goal-tracking whether rats are given nicotine or
saline on the test sessions. Finally, a reduction in goal-tracking brought about by MK-801
administration would suggest that MK-801 may be able to generally disrupt discriminated
goal-tracking. To assess this hypothesis, a follow-up study using saline as the CS paired
with sucrose deliveries and intermixed sucrose-free nicotine sessions (i.e., the opposite
contingency as that in Experiment 1) was conducted to determine whether MK-801
pretreatment of the saline CS would reduce goal-tracking for sucrose similar to Experiment
1 and in Murray and Bevins (2007a).
Materials and methods
Subjects
Male Sprague–Dawley rats obtained from Harlan (Indianapolis, IN, USA) were housed
individually in clear 48.3×26.7×20.3 cm (l×w×h) polycarbonate cages lined with aspen
shavings. Water was continuously available in the home cage. Rats received food (Harlan
Teklad Rodent Diet) after completion of daily sessions; the quantity was restricted as to
maintain rats at 85% of free-feeding body weights. All sessions were conducted during the
light portion of a 12 h light:dark cycle. Protocols were approved by the University of
Nebraska—Lincoln Animal Care and Use Committee and followed the ‘Guidelines for the
Care and Use of Mammals in Neuroscience and Behavioral Research’ (National Research
Council 2003).
Apparatus
Each of the eight conditioning chambers (ENV-008CT; Med Associates, Inc., St. Albans,
VT, USA), measuring 30.5×24.1×21.0 cm (l×w×h), had aluminum sidewalls. The ceiling
and front and back walls were clear polycarbonate. Each chamber was equipped with a
5.2×5.2×3.8 cm (l×w×d) recessed receptacle on one sidewall. A dipper arm raised a 0.1-ml
cup of 26% sucrose solution (w/v) into the receptacle. An infrared emitter/detector unit, 1.2
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cm into the receptacle and 3 cm from the chamber floor, monitored head entries. A second
emitter/detector unit was mounted 14.5 cm from the sidewall with the receptacle and
positioned 4 cm above the rod floor. Interruptions of this infrared beam provided an index of
movement in the chamber. Each chamber was enclosed in a light- and sound-attenuating
cubicle fitted with an exhaust fan. A personal computer with Med Associates interface and
software (Med-PC for Windows, version IV) controlled sucrose deliveries and recorded
dipper entries and activity.
Drugs
(−)-Nicotine hydrogen tartrate, mecamylamine hydrochloride, and 1-
aminocyclopropanecarboxylic acid hydrochloride (ACPC) were purchased from Sigma (St.
Louis, MO, USA). (+)-MK 801 maleate, Ro 25-6981 hydrochloride, CGP 39551, d-CPPene,
N-methyl-D-aspartic acid (NMDA), and L-701,324 were purchased from Tocris Cookson,
Inc. (Ellisville, MO, USA). PCP was generously provided by the NIDA drug supply
program (RTI, Research Triangle Park, NC, USA). Vehicle, route of administration,
injection volume, and injection-to-placement interval are described in Table 1. Nicotine
doses are reported in base form; all other doses are reported in salt form.
Experiment 1
Discrimination training (Nic+/Sal−)—Sixteen experimentally naïve rats (363±16 g
before start of study) were handled for at least 3 min per day for 3 days. Rats were then
given an injection of 0.4 mg/kg nicotine for the next 3 days in the home cage to attenuate the
initial motor suppressant effects of nicotine (cf. Bevins et al. 2001). Daily training began the
next day. Rats were administered nicotine or saline SC 5 min before placement in the
chambers for 20 min. During nicotine sessions, there were 36 deliveries of 4-s access to
sucrose. Four different programs were used to vary the time between sucrose deliveries. The
average time before the first sucrose delivery was 137 s (range=124–152 s); the inter-
sucrose interval thereafter ranged from 4 to 80 s (mean=25 s). In order to match timing on
saline sessions, programs were matched to the nicotine programs such that 4-s ‘empty’
intervals occurred in place of sucrose deliveries. Session types and programs were
intermixed with the restriction that no more than two nicotine or two saline sessions
occurred in a row. Training continued for eight nicotine and eight saline sessions.
Antagonism and substitution testing—Following acquisition of the discrimination,
rats entered testing. On the first four consecutive days of a 5-day cycle, rats received two
nicotine and two saline training sessions as described earlier. If the discrimination criterion
was met, then day 5 was a 4-min test session; sucrose was not available in testing. To
qualify for testing, the dipper entry rate on each nicotine session had to be a minimum of
0.01 entries per second higher than each saline session across the four training days of a
testing cycle (cf. Murray and Bevins 2007b). If the criterion was not met, then the rat
remained in its home cage on day 5. The order of testing phases, drugs used, and doses is
given in Table 2. Within each phase, test order of each dose was randomized for each rat. A
rat completed one phase before progressing to the next phase.
Experiment 2a
Excitatory conditioning (no saline sessions)—Eight experimentally naïve rats
(349±21 g before start of study) were handled, maintained, and given pre-training nicotine
as in Experiment 1. Daily training sessions began the day following the last nicotine
injection. Rats were administered saline (IP) 25 min before 0.4 mg/kg nicotine (SC); rats
were placed in the chamber 5 min after the nicotine injection. Saline injections were given to
familiarize rats with IP administration and the timing of the injections in the testing phase.
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During the 20-min sessions, there were 36 deliveries of 4-s access to sucrose. The programs
that provided access to sucrose from Experiment 1 were used here. There were no saline
(i.e., sucrose-free) sessions. Excitatory conditioning continued for 20 days.
State-change testing—Testing of different drug states followed conditioning. In order to
qualify for a test session, conditioned responding had to be stable. Stable was defined as no
statistically significant difference in rate of dipper entries for at least three training sessions.
Rats were given two injections before each 4-min sucrose-free test. Drug details for the tests
are provided in Table 3. Test order assignment was randomized for each rat. Training
intervened between each test to insure that responding was stable.
Experiment 2b
Discrimination training (Sal+/Nic−)—Seven experimentally naïve rats (292±2 g before
start of study) were handled, maintained, and trained as described in Experiment 1 except
for one major difference—sucrose was delivered on saline sessions, not on intermixed 0.4
mg/kg nicotine sessions (nicotine as a CS−; see Besheer et al. 2004). Training continued for
eight nicotine and eight saline sessions.
Antagonism testing—Qualification for testing was established as described in
Experiment 1. Each rat was tested on 0, 0.03, 0.1, and 0.2 mg/kg MK-801 administered
before saline test sessions in a unique random order.
Dependent measures
The dependent measure for training was the rate of dipper entries per second before the first
sucrose delivery or equivalent time on sucrose-free sessions. The dependent measure for test
sessions was dipper entry rate in the first 2 min of the test; this interval approximates the
average time before the first sucrose delivery during the training phase (cf. Besheer et al.
2004). Chamber activity, defined as rate of beam breaks per second in the time comparable
to that for dipper entries, was also monitored.
Data analysis
For Experiments 1 and 2b, acquisition of the discrimination was confirmed using a paired t
test to compare the mean (M) of the last three nicotine and saline training sessions. For
generalization, antagonism, and substitution testing, one-way analyses of variance
(ANOVAs) compared dose of ligand for dipper entry and activity rates. Significant
ANOVAs were followed by Dunnett’s multiple-comparison tests contrasting each test dose
with its corresponding vehicle baseline. Significant Dunnett’s tests were followed with
paired t tests comparing the effective dose with the training baseline to determine if
blockade was partial or full (effect reduced but not to the level of baseline responding, or
reduced to the level of baseline responding, respectively). Median effective doses (ED50s)
were calculated on the linear portions of nicotine generalization curve and on antagonism
tests that resulted in full blockade of conditioned responding. In Experiment 2a, stability of
goal-tracking was assessed using one-way ANOVAs. For testing, one-way ANOVAs
compared the drug states for dipper entry and activity rates. A significant ANOVA during
testing was followed by Dunnett’s multiple-comparison tests contrasting each test condition
to the baseline conditioning state (i.e., Sal-Nic). For all experiments, statistical significance
was declared at p<0.05.
Murray et al. Page 5
Psychopharmacology (Berl). Author manuscript; available in PMC 2012 January 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Results
Experiment 1
Discrimination training—Dipper entry rates were higher on nicotine than saline by the
end of training, t(15)=7.65, p<0.001 (Ms=0.178±0.02 vs. 0.081±0.01 on nicotine vs. saline
sessions, respectively). There was no difference in activity, t<1 (Ms=0.388± 0.03 and
0.381±0.04 on nicotine and saline sessions, respectively).
Antagonism and substitution testing
Nicotine generalization: As shown in Fig. 1a, there was an increase in conditioned
responding with 0.2 mg/kg, followed by a reduction in conditioned responding as the
nicotine dose decreased toward saline, F(5,75)=13.54, p< 0.001. Post-hoc analysis
confirmed this impression of increased responding at 0.2 mg/kg nicotine. Additionally,
saline and 0.025 mg/kg evoked lower responding than 0.4 mg/kg. The ED50 for nicotine was
0.084 mg/kg. There was an effect of nicotine on chamber activity, F(5,75)= 3.75, p<0.01
(see Table 4). Activity on 0.1 and 0.2 mg/kg nicotine was higher than responding on saline;
there were no differences in activity when compared with 0.4 mg/kg.
MK-801 and PCP antagonism: MK-801 and PCP dose-dependently decreased nicotine-
evoked conditioned responding (Fig. 1b). For MK-801, there was a main effect of dose,
F(3,42)=14.26, p<0.001, with subsequent contrasts indicating that 0.1 and 0.2 mg/kg
MK-801 significantly reduced the CR relative to nicotine alone. Follow-up t tests compared
0.1 and 0.2 mg/kg doses of MK-801 to a saline baseline (M=0.035±0.004) generated using
the last saline training session for each rat before testing with 2 mg/kg PCP. Antagonism
with 0.1 mg/kg MK-801 was partial, t(14)=3.37, p<0.01, yet antagonism with 0.2 mg/kg was
full, t<1. The ED50 for MK-801 was 0.104 mg/kg. For PCP, there was a main effect of dose,
F(3,42)=3.44, p<0.05. The 2 mg/kg PCP dose reduced goal-tracking evoked by the nicotine
CS, but that reduction was only partial, t(14)=2.84, p<0.05. PCP at 3 mg/kg profoundly
inhibited locomotor activity (data not shown) in the first few rats tested so we ceased testing
doses greater than 2 mg/kg. Table 4 shows neither MK-801 nor PCP affected chamber
activity at the doses that were fully tested, Fs≤1.71, ps≥0.18.
CGP 39551 d-CPPene, and Ro 25-6981 antagonism: Rather than reducing responding
evoked by nicotine, some competitive NMDA receptor antagonists increased the nicotine-
evoked CR (Fig. 1c). For CGP 39551 there was main effect of dose, F(4,56)=3.58, p<0.05;
10 mg/kg CGP 39551 evoked greater responding than nicotine alone. Similarly, for Ro
25-6981, there was a main effect of dose, F(4,56)=3.60, p<0.05; 1, 3, and 10 mg/kg Ro
25-6981 enhanced nicotine-evoked responding compared to nicotine alone. There was no
effect of d-CPPene, F(4,56)=1.64, p=0.18. CGP 39551 and Ro 25-6981 had no significant
effect on activity, Fs≤2.12, ps≥0.09 (see Table 4). Although the ANOVA on activity for d-
CPPene was significant, F(4,56)=4.45, p< 0.01, the post-hoc comparisons did not indicate
any significant differences.
NMDA and Ro 25-6981 substitution: Neither NMDA nor Ro 25-6981 substituted for the
nicotine CS (Fig. 1d). Although the ANOVA was significant for NMDA, F(3,39)=5.28,
p<0.01, the post-hoc comparisons did not reveal any significant differences. The ANOVA
was not significant for Ro 25-6981, F(3,36)=1.78, p=0.17. As listed in Table 4, NMDA and
Ro 25-6981 affected chamber activity. There was a main effect of NMDA, F(3,39)=4.86,
p<0.01; 30 mg/kg NMDA reduced chamber activity compared to saline. Conversely, Ro
25-6981, F(3,36)= 6.80, p<0.001, significantly enhanced activity at 10 mg/kg.
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ACPC and L-701,324 antagonism: As shown in Fig. 1e, ACPC reduced nicotine-evoked
conditioned responding. The ANOVA was significant, F(3,39)=6.01, p<0.01; dipper entries
were reduced at 100 and 500 mg/kg but not at 300 mg/kg ACPC. Responding following
pretreatment with 100 and 500 mg/kg was not decreased to the saline baseline
(M=0.029±0.004) generated from the last saline training session before testing on 300 mg/kg
ACPC, ts (13)≥4.33, ps<0.001, indicating partial antagonism. There was no effect of ACPC
on activity, F<1 (Table 4). L-701,324 reduced nicotine-evoked conditioned responding, but
only at doses that also significantly decreased activity (data not shown). As such, we cannot
interpret whether dipper entry reduction reflects antagonism of the CS effects of nicotine or
general motor impairment.
Experiment 2a
Treatment with 0.2 mg/kg MK-801 reduced dipper entry rates regardless of whether it was
given before nicotine or before saline (Fig. 2a). There was a main effect of drug state,
F(5,35)=5.15, p<0.001. Post-hoc contrasts indicate that only MK-801 reduced conditioned
responding compared to the Sal-Nic baseline (training) condition. Although the ANOVA on
activity was significant, F(3,35)=2.91, p< 0.05, there were no differences relative to the Sal-
Nic condition (Table 5).
Experiment 2b
Discrimination training—Dipper entry rates were higher on saline than nicotine by the
end of training, t(6)=3.84, p= 0.009 (Ms=0.266±0.06 vs. 0.086±0.01 on saline vs. nicotine
sessions, respectively). There was also a difference in chamber activity, t(6)=4.34, p=0.005
(Ms=0.307±0.05 vs. 0.495±0.02 on saline vs. nicotine sessions, respectively).
MK-801 antagonism—MK-801 dose-dependently decreased saline-appropriate
responding (Fig. 2b). The one-way ANOVA was significant, F(3,27)=5.33, p=0.008.
Subsequent contrasts indicating that 0.2 mg/kg MK-801 reduced the CR relative to saline
alone to the level of the nicotine baseline (M=0.096± 0.02) generated using the last nicotine
training session for each rat before testing with 0.1 mg/kg MK-801 (t<1). The ED50 for
MK-801 was 0.105 mg/kg. Table 5 shows that MK-801 dose-dependently increased
chamber activity, F(3,27)= 9.81, p<0.001, with the 0.2 mg/kg dose greater than saline
treatment and reaching the level of the nicotine activity baseline, M=0.529±0.05, t(6)=2.29,
p=0.06.
Discussion
The findings of the present report replicate and extend our previous research demonstrating
the nicotine-evoked CR was dose-dependently blocked by MK-801 (Murray and Bevins
2007a). We found a similar effect in the present study with full antagonism of the nicotine
(0.4 mg/kg)-evoked CR at 0.2 mg/kg MK-801. We extended these findings by testing PCP,
another NMDA channel blocker, that has a slightly lower affinity for NMDA receptors than
MK-801 (Wong et al. 1986) but still produces similar discriminative stimulus effects to
MK-801 (e.g., Chaperon et al. 2003; Doty et al. 1994; Willetts and Balster 1988). PCP
pretreatment (2 mg/kg) partially blocked the nicotine-evoked CR. However, no other ligand
acting on the NMDA receptor fully blocked nicotine-evoked responding without profoundly
altering motor activity (i.e., L-701,324). The only other consistent effect was an
enhancement of nicotine-evoked conditioned responding when pretreated with Ro 25-6981,
a highly selective antagonist of the NR2B receptor subtype (Fischer et al. 1997; Lynch et al.
2001; Mutel et al. 1998). In contrast, CGP 39551 and d-CPPene, specific but non-selective
antagonists for NR2A/B NMDA receptor binding sites (Davies et al. 1986; Fagg et al. 1990;
Lowe et al. 1994), had only minor effects on the CR. The enhanced responding found with
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the high dose of CGP 39551 may reflect some preferential binding to the NR2B subtype
over the NR2A subtype at the higher dose making it act similar to Ro 25,6981 (see Blaise et
al. 2005).
A possible explanation for nicotine-enhanced responding with Ro 25-6981 is based on the
observation that rats trained with 0.4 mg/kg nicotine can show an increase in responding
when tested with 0.2 mg/kg in the DGT (Murray and Bevins 2007a) and operant drug
discrimination (e.g., Pratt et al. 1983) tasks suggesting a possible performance-impairing
effect of that higher nicotine dose. Although it is unclear what behavioral process may be
affected (motor, appetite, etc.), the underlying mechanism could involve NR2B receptors.
NR2B-containing receptors tend to be localized extrasynaptically and function to slow
glutamatergic synaptic transmission in highly active synapses (Li et al. 2002; Massey et al.
2004; Stocca and Vicini 1998; Woodhall et al. 2001). Blocking these receptors can result in
increased synaptic transmission, including transmission evoked by nicotine, which may in
turn contribute to the enhanced behavioral output (CR) evoked by the nicotine CS. Although
Ro 25-6981 increased responding to the nicotine CS, it did not substitute for nicotine when
given alone, suggesting a lack of tonic NMDA activity in the absence of nicotine. Further,
NMDA did not substitute for the nicotine CS, indicating that NMDA activation cannot be
solely responsible for the nicotine-evoked CR regardless of the CR-attenuating effects of the
channel blockers, MK-801 and PCP.
NMDA receptors have both NMDA (NR2) and glycine/D-serine (NR1) binding sites, and
there is a general consensus that binding of both sites is required for NMDA receptor
activation (e.g., Clements and Westbrook 1991; Kemp and Leeson 1993; Wolosker 2007).
As glycine is acting as a co-agonist with NMDA and as it is often found in high tonic
concentrations in vivo (Johnson and Ascher 1987), blocking this binding site should prevent
NMDA receptor activation. As such, we tested L-701,324, a selective glycine antagonist at
the NMDA receptor complex (Bristow et al. 1995; Rowley et al. 1993), to determine if the
glycine binding site is the primary mechanism for the NMDA receptor component of the
nicotine-evoked CR. Unfortunately, this compound decreased responding at doses that also
attenuated locomotor activity making interpretation difficult. Nicotine co-administration
with ACPC, a partial agonist at the NMDA receptor having agonist actions at the glycine/D-
serine (NR1) binding site and antagonist actions at the NMDA (NR2) binding site (Nahum-
Levy et al. 1999; Sheinin et al. 2002), should enhance the nicotine-evoked CR if there was a
glycine component; attenuation of the CR should be seen if there was an NMDA
component. We found some inconsistent partial antagonism with ACPC, suggesting again a
possible NMDA role for the CS effects of nicotine.
Although the results from Experiment 1 hint at some role of NMDA activation in the CS
effects of nicotine (cf. Ro 25-6981 and ACPC), there was no clear mechanism of the
MK-801/PCP reduction in conditioned responding identified in that experiment. This
outcome prompted us to examine whether reduction of the CR by MK-801 reflected a state-
dependency effect. As detailed in the Introduction, there is extensive evidence that behaviors
learned under the influence of MK-801 are not expressed in the absence of MK-801 (e.g.,
Schmidt et al. 1999). Further, and directly relevant to the current study, behaviors learned in
the absence of MK-801 may no longer be expressed when tested in the presence of MK-801
(e.g., Wise et al. 1996). This state-dependency account would suggest that when we tested
MK-801 pretreatment of the nicotine CS, MK-801 altered the state of the rats, preventing
them from recalling the nicotine CS-sucrose US association and subsequently reducing their
CR.
The results of Experiment 2a confirmed the predictions outlined in the Introduction. That is,
removing nicotine or administering mecamylamine had no effect on goal-tracking
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presumably because the chamber cues and not the nicotine state were evoking the CR—
recall that sucrose and nicotine occurred on every session (cf., Bevins et al. 2007). In
contrast, administration of MK-801 significantly reduced the goal-tracking CR without
impacting locomotor activity. This disruption was seen whether saline or nicotine was also
administered before the test, and is consistent with the suggestion that pretreatment with
MK-801 prevented recall of the chamber CS-sucrose US association. By extension, MK-801
in Experiment 1 and in Murray and Bevins (2007a) may be preventing recall of the nicotine
CS-sucrose US association in the DGT task rather than pharmacologically blocking the
nicotine. Experiment 2b reversed the DGT contingencies so that sucrose was delivered on
saline, but not on nicotine sessions. Thus, goal-tracking was high only on saline sessions;
responding withheld on nicotine sessions. Pretreatment with MK-801 on saline test sessions
dose-dependently reduced goal-tracking to the low level seen on nicotine sessions; the linear
regression analyses used to establish ED50s for each of the MK-801 dose effect curves were
not different, F(1,2)=4.77, p=0.16. Combined, these results suggest that the effect of
MK-801 in the DGT task was not specific to nicotine but instead disrupted discriminated
goal-tracking responding by virtue of its state-changing effects.
The present results are especially interesting in light of previous research with nicotine as an
operant discriminative stimulus. That research has shown that pretreatment with MK-801
and agmatine, another NMDA receptor antagonist (Yang and Reis 1999), did not affect
nicotine-appropriate responding or overall response rates (Kim and Brioni 1995; Zakharova
et al. 2005; Zaniewska et al. 2008). Importantly, the lack of effect on response rates in the
operant literature indicates that motivation for the reinforcer was not affected—thereby
suggesting the reduction in dipper entries in the current studies is unlikely due to reduced
motivation for sucrose. Rather, there appears to be dissociation in the state-dependency
effect of MK-801 in the DGT and two-lever drug discrimination tasks. Perhaps the explicit
contingency between lever pressing and reinforcement delivery makes lever pressing more
resistant to this effect of MK-801; dipper entries in the DGT task are not required for
delivery of the reinforcer, nor does the frequency of head entries into the dipper change the
rate of reinforcement. However, this explanation seems unlikely as Jackson et al. (1992)
found that rats trained to press a single lever using food reinforcement in a saline state had
responding severely disrupted when treated with MK-801 or PCP. Future research
investigating the nature of the associative learning in these different tasks and their
underlying mechanisms could suggest improved behavioral and pharmacological approaches
to treating nicotine addiction (see Bevins 2009 and Wooters et al. 2009).
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Fig. 1.
Panel a shows dipper entry rate ± SEM for nicotine generalization tests. Panel b shows
dipper entry rate ± SEM for antagonism tests with MK-801 and PCP. The solid line
indicates the saline baseline dipper entry rate generated from the saline training session
before each rat tested with 2 mg/kg PCP (dotted lines ± SEM). Panel c shows dipper entry
rate ± SEM for antagonism testing with CGP 39551, d-CPPene, and Ro 25-6981. Panel d
shows dipper entry rate ± SEM for substitution testing with NMDA and Ro 25-6981. Panel e
shows dipper entry rate ± SEM of antagonism testing with ACPC. The solid line indicates
saline baseline dipper entry rate generated from the saline training session before each rat
tested with 300 mg/kg ACPC (dotted lines ± SEM). For all panels, # indicates difference
from vehicle baseline, p<0.05; ##p<0.01; ###p<0.001. * indicates difference from vehicle
pretreatment of nicotine or nicotine alone, p<0.05; **p<0.01; *** p<0.001. ^ indicates main
effect of test drug in the absence of significant post-hoc comparisons
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Fig. 2.
Panel a shows dipper entry rate + SEM of the state-change testing in Experiment 2a. Panel b
shows dipper entry rate ± SEM of antagonism testing with MK-801 of the saline CS in
Experiment 2b. The solid line indicates nicotine baseline dipper entry rate generated from
the nicotine training session before each rat tested with 0.1 mg/kg MK-801 (dotted lines ±
SEM). For both panels, * indicates difference from vehicle pretreatment of nicotine or
nicotine alone, p< 0.05; **p<0.01; ***p<0.001
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